Browsing Tag
Emergent BioSolutions
7 posts
Syngene expands global footprint with US biologics manufacturing facility acquisition
Syngene International Limited, a leading contract research, development, and manufacturing organization (CRDMO), has acquired its first biologics manufacturing…
Emergent BioSolutions introduces next-generation anthrax vaccine
Emergent BioSolutions, a leader in public health preparedness, has introduced a cutting-edge anthrax vaccine aimed at enhancing global…
Hikma Pharmaceuticals partners with Emergent BioSolutions to expand access to KLOXXADO nasal spray
Hikma Pharmaceuticals PLC has announced an exclusive partnership with Emergent BioSolutions to commercialise KLOXXADO (naloxone HCl) nasal spray…
Emergent BioSolutions’ ACAM2000 receives FDA approval for Mpox prevention
Emergent BioSolutions Inc. (NYSE: EBS) has achieved a notable milestone with the U.S. Food and Drug Administration (FDA)…
Narcan nasal spray becomes the first OTC naloxone product approved by the FDA for opioid overdose treatment
Emergent BioSolutions’ Narcan nasal spray is now FDA-approved for over-the-counter use. Find out how this could change the fight against opioid overdoses.
Bavarian Nordic to acquire Vivotif and Vaxchora travel vaccines from Emergent BioSolutions
Bavarian Nordic A/S will acquire two oral vaccines from Emergent BioSolutions for a total consideration of up to…
Emergent BioSolutions begins phase 3 trial of CHIKV VLP vaccine candidate
Emergent BioSolutions said that it has dosed the first participant in a phase 3 clinical trial of CHIKV…